Sector Update: Healthcare Stocks Mixed Premarket Tuesday

MT Newswires Live07-14 21:15

Healthcare stocks were mixed premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.3% and the iShares Biotechnology ETF (IBB) 0.1% higher.

HCA Healthcare (HCA) shares were down more than 9% after the company cut its 2026 adjusted diluted EPS guidance.

NextCure (NXTC) will merge with privately held Avere Therapeutics in an all-stock transaction to advance Avere's lead oral IL-23 therapy, AVR-001, for inflammatory diseases, the company said. NextCure shares were surging past 313% pre-bell.

Spero Therapeutics (SPRO) has licensed exclusive worldwide rights, excluding Greater China, to develop and commercialize Innovent Biologics' immunology drug candidate, IBI355, under a deal valued at up to about $1.1 billion, the companies said. Spero Therapeutics stock was up 0.5% premarket.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2651060081?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651060081","market":"sh","top_or_hot":-1,"title":"Sector Update: Healthcare Stocks Mixed Premarket Tuesday","media":"MT Newswires Live","content":"<html><body><p> Healthcare stocks were mixed premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.3% and the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB) 0.1% higher.</p><p>HCA Healthcare (HCA) shares were down more than 9% after the company cut its 2026 adjusted diluted EPS guidance.</p><p>NextCure (NXTC) will merge with privately held Avere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> in an all-stock transaction to advance Avere's lead oral IL-23 therapy, AVR-001, for inflammatory diseases, the company said. NextCure shares were surging past 313% pre-bell.</p><p>Spero Therapeutics (SPRO) has licensed exclusive worldwide rights, excluding Greater China, to develop and commercialize <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a>' immunology drug candidate, IBI355, under a deal valued at up to about $1.1 billion, the companies said. Spero Therapeutics stock was up 0.5% premarket.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sector Update: Healthcare Stocks Mixed Premarket Tuesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSector Update: Healthcare Stocks Mixed Premarket Tuesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-14 21:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Healthcare stocks were mixed premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.3% and the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB) 0.1% higher.</p><p>HCA Healthcare (HCA) shares were down more than 9% after the company cut its 2026 adjusted diluted EPS guidance.</p><p>NextCure (NXTC) will merge with privately held Avere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> in an all-stock transaction to advance Avere's lead oral IL-23 therapy, AVR-001, for inflammatory diseases, the company said. NextCure shares were surging past 313% pre-bell.</p><p>Spero Therapeutics (SPRO) has licensed exclusive worldwide rights, excluding Greater China, to develop and commercialize <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a>' immunology drug candidate, IBI355, under a deal valued at up to about $1.1 billion, the companies said. Spero Therapeutics stock was up 0.5% premarket.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014005.SGD","symbol_name":"United Global Durable Equities Fund Acc SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2651060081","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651060081","pubTimestamp":1784034940,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Healthcare stocks were mixed premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF  down 0.3% and the iShares Biotechnology ETF  0.1% higher.HCA Healthcare  shares were down more than 9% after the company cut its 2026 adjusted diluted EPS guidance.NextCure  will merge with privately held Avere Therapeutics in an all-stock transaction to advance Avere's lead oral IL-23 therapy, AVR-001, for inflammatory diseases, the company said. NextCure shares were surging past 313% pre-bell.Spero Therapeutics  has licensed exclusive worldwide rights, excluding Greater China, to develop and commercialize Innovent Biologics' immunology drug candidate, IBI355, under a deal valued at up to about $1.1 billion, the companies said. Spero Therapeutics stock was up 0.5% premarket.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","IBB":"生物科技指数ETF-iShares Nasdaq","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","HCA":"HCA控股","NXTC":"Nextcure Inc.","XLV":"健康照护类股ETF-SPDR","BK4504":"桥水持仓","LU1150488218.USD":"First Eagle Amundi Income Builder AU2-MD USD","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","BK4588":"碎股","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","HCSG":"Healthcare Svcs Group Inc","LU0882574055.USD":"富达全球健康医疗A ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4185":"保健护理机构","LU1150488135.SGD":"First Eagle Amundi Income Builder AHS-MD SGD-H","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","BK4137":"综合支持服务","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","IHF":"iShares Dow Jones U.S. Health Ca","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","BK4581":"高盛持仓","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","SPRO":"Spero Therapeutics Inc.","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LABU":"三倍做多标普生物-Direxion","XBI":"SPDR S&P Biotech ETF","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","BK4585":"ETF&股票定投概念","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4139":"生物科技","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD"},"translate_title":"行业更新：周二盘前医疗保健股涨跌互现","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IHF":0.6,"SPRO":1,"HCA":1,"XBI":0.6,"IBB":1,"HCSG":1.5,"NXTC":1,"XLV":1.5,"LABU":0.6},"content_text":"Healthcare stocks were mixed premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.3% and the iShares Biotechnology ETF (IBB) 0.1% higher.HCA Healthcare (HCA) shares were down more than 9% after the company cut its 2026 adjusted diluted EPS guidance.NextCure (NXTC) will merge with privately held Avere Therapeutics in an all-stock transaction to advance Avere's lead oral IL-23 therapy, AVR-001, for inflammatory diseases, the company said. NextCure shares were surging past 313% pre-bell.Spero Therapeutics (SPRO) has licensed exclusive worldwide rights, excluding Greater China, to develop and commercialize Innovent Biologics' immunology drug candidate, IBI355, under a deal valued at up to about $1.1 billion, the companies said. Spero Therapeutics stock was up 0.5% premarket.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651060081","isCrawlerRequest":true}